Loading…
Chinese biotechnology company; specific product lines not confirmed from available knowledge.
Chinese biotechnology company; specific product lines not confirmed from available knowledge.
Moat: none
Headquarters: China · Employees: 3,126
Size Yili Chuanning Biotechnology (301301.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.70B, the 953rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.07 on 6 Nov 2026.
Performance Over six months the shares fell 19.5%, against -3.4% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 14.2% over the last twelve months (peer median +16.5%); the operating margin is 15.6% (peer median 10.6%).
Valuation It trades at 26.3× forward earnings against a peer median of 44.2× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.5 points above its cost of capital (6.2% WACC).
Next results Next results expected around 6 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.06B | CN¥4.58B | CN¥5.71B | CN¥4.78B | CN¥3.79B |
| Revenue growth | — | -20% | +19% | +26% | — |
| Gross profit | CN¥1.35B | CN¥1.27B | CN¥2.00B | CN¥1.45B | CN¥876M |
| EBITDA | n/a | CN¥1.56B | CN¥2.30B | CN¥1.74B | CN¥1.22B |
| Net income | CN¥490M | CN¥769M | CN¥1.40B | CN¥941M | CN¥412M |
| Free cash flow | CN¥713M | CN¥452M | CN¥1.75B | CN¥947M | CN¥644M |
| Capital expenditure | CN¥87.5M | CN¥97.2M | CN¥42.6M | CN¥345M | CN¥47.2M |
| Total debt | CN¥1.24B | CN¥1.39B | CN¥1.57B | CN¥2.23B | CN¥3.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301301.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.5% | +1.2% | 9th lowest of 21 |
| 6-month return | -19.5% | -3.4% | 5th lowest of 21 |
| Distance from 52-week high | -37.4% | -23.9% | 7th lowest of 21 |
| Revenue growth (TTM) | -14.2% | +16.5% | 3rd lowest of 20 |
| Operating margin | 15.6% | 10.6% | 8th highest of 19 |
| Forward P/E | 26.3× | 44.2× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 4.6% | 16.3% | 7th least demanding of 15 |
| Growth delivered (Del g) | +4.8% | +10.5% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | -0.2 pp | +2.4 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +3.5 pp | -1.1 pp | 7th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yili Chuanning Biotechnology 301301.SZ | China | $2.70B | -20% | -14% | 16% | 26.3× | 4.6% | +4.8% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.68B | +14% | +50% | 26% | 54.3× | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.72B | +95% | +29% | 17% | 64.9× | 45.0% | +27.7% |
| Almirall ALM.MC | Spain | $2.74B | -2% | +24% | 8% | 30.6× | 7.3% | +6.5% |
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | n/a | n/a | n/a |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 53.4× | 25.7% | +100.1% |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 100.0× | 42.1% | +22.9% |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 76.2× | 50.7% | +17.3% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% | +19.3% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 15.6× | -13.1% | +2.4% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | n/a | n/a | n/a |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 18.6× | n/a | n/a |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 44.2× | 25.2% | +14.0% |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | n/a | n/a | n/a |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 51.4× | 40.1% | +6.1% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 17.0× | -9.1% | -1.5% |
| InnoCare Pharma 688428.SS | China | $2.31B | -2% | +135% | 35% | 94.3× | -8.8% | +344.2% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | n/a | -2.2% | -5.8% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 21.3× | -2.2% | +7.0% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 26.2× | 1.6% | +0.3% |